Eukaryotic Transcription Inhibitors
Tonsillitis II: Management
Dipeptidyl Peptidase 4 Inhibitors
Impression Management Techniques I: Managing Appearances
Types of RNA
Types of Hormones
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Updated: Feb 8, 2026

A High-Throughput Luciferase Assay to Evaluate Proteolysis of the Single-Turnover Protease PCSK9
Published on: August 28, 2018
Muhammed Shahreyar1, Salem A Salem1, Mannu Nayyar1
1From Division of Cardiology, Department of Medicine, University of Tennessee Health Sciences Center, Memphis, TN (MS, SAS, MN, NG, SKGK); Division of Nephrology, Department of Medicine, University of Tennessee Health Sciences Center, Memphis (LKG); Department of Physician Assistant Studies, University of Tennessee Health Sciences Center, Memphis (LKG); Regional One Health, Memphis (SKGK).
New proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors offer an alternative to statins for managing hyperlipidemia. These agents effectively lower low-density lipoprotein cholesterol, especially for statin-intolerant patients or those needing additional lipid reduction.
Area of Science:
Background:
Purpose of the Study:
Main Methods:
Main Results:
Conclusions: